Identifying a small-molecule drug that can effectively treat (or potentially cure) patients with sickle cell disease (SCD) around the world is something of a Holy Grail in hematology research and drug ...
Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...
Reuters and The Wall Street Journal have punctured investors’ hopes that Novartis will buy Cytokinetics. Both outlets have reported that the Swiss drugmaker is backing away from the potential deal ...
Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a conditional payment tied to the timely FDA approval of atrasentan without a ...
EAST HANOVER, N.J., July 3, 2025 /PRNewswire/ -- Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback